We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Oncology

Oncology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin
Diabetes & Endocrinologyantithyroglobulin antibodiesPapillary Thyroid Carcinoma

Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin

By MedXY|Jun 3, 2026

In papillary thyroid carcinoma treated with thyroidectomy and RAI, TgAb levels above the assay’s limit of quantification identified patients with higher long-term recurrence risk despite undetectable serum thyroglobulin.

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
newsbreast cancerprogression-free survival

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY|Aug 18, 2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.

Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma
Hematology-Oncologyixazomibmultiple myeloma

Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma

By MedXY|Jun 2, 2026

A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS
Hematology-OncologyAllogeneic Hematopoietic Cell TransplantationAML

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS

By MedXY|Jun 2, 2026

A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and enc

Pancreatic Cancer Risk During IPMN Surveillance Is About 10-Fold Higher Than in the General Population
GastroenterologyIPMNpancreatic adenocarcinoma

Pancreatic Cancer Risk During IPMN Surveillance Is About 10-Fold Higher Than in the General Population

By MedXY|Jun 1, 2026

A SEER-matched analysis found that patients undergoing IPMN surveillance have a markedly elevated malignancy risk, with substantial heterogeneity by duct dilation, obesity, age, and cyst features.

Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison
GastroenterologyIPMNPancreatic Cancer

Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison

By MedXY|Jun 1, 2026

A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.

More Than Half of Patients With Atypical Endometrial Hyperplasia Had Occult Cancer at Hysterectomy in a Minority-Enriched Urban Cohort
newsHealth InequityEndometrial Carcinoma

More Than Half of Patients With Atypical Endometrial Hyperplasia Had Occult Cancer at Hysterectomy in a Minority-Enriched Urban Cohort

By MedXY|Aug 18, 2026

A single-center retrospective study found unexpectedly high rates of concurrent endometrial carcinoma and Mayo-criteria risk features among patients with atypical endometrial hyperplasia in a predominantly racial and ethnic minority populat

Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer
newscancermental health

Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer

By MedXY|May 31, 2026

A national study of veterans with cancer found elevated suicide-related risk that persisted for years, especially among younger, unmarried, frail, or mentally ill patients and those with certain cancers such as central nervous system and th

Targeting Ibrutinib Resistance Pathways with miR-28 in ABC-DLBCL
Hematology-OncologyABC-DLBCLBTK inhibitor

Targeting Ibrutinib Resistance Pathways with miR-28 in ABC-DLBCL

By MedXY|May 29, 2026

miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.

When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed
newscancer disparitieslung cancer

When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed

By MedXY|May 29, 2026

A large Japanese study found that people with schizophrenia spectrum disorders were less likely to receive several standard treatments for non-small cell lung cancer, underscoring a persistent and preventable gap in cancer care.

Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in Japan
newsJapanNon-Small Cell Lung Cancer

Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in Japan

By MedXY|May 29, 2026

A nationwide Japanese cohort study found that patients with schizophrenia spectrum disorder and NSCLC presented with more advanced disease and were less likely to receive surgery, adjuvant chemotherapy, or systemic therapy.

Embedding Tobacco Treatment Into Cancer Care Achieved Universal Screening but Exposed Persistent Gaps in Cessation Assistance
newscancer careelectronic medical record

Embedding Tobacco Treatment Into Cancer Care Achieved Universal Screening but Exposed Persistent Gaps in Cessation Assistance

By MedXY|May 29, 2026

A cancer program quality improvement initiative reached a 100% smoking-status ask rate through an electronic hard stop, but assistance for identified smokers remained inconsistent, underscoring the implementation gap between screening and e

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma
newsimmune checkpoint inhibitorsrecurrent vulvar cancer

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

By MedXY|Aug 18, 2026

This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.

Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer
Gastroenterologyimmune suppressionKRAS G12D

Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer

By MedXY|May 28, 2026

Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models
Hematology-OncologyAMLBệnh Bạch Cầu Tế Bào Phôi

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models

By MedXY|May 27, 2026

MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.

Volumetric Thresholds After Glossectomy May Predict Feeding Tube Dependence and Poor Speech
newsflap reconstructionglossectomy

Volumetric Thresholds After Glossectomy May Predict Feeding Tube Dependence and Poor Speech

By MedXY|May 27, 2026

A retrospective cohort study suggests that preoperative tumor burden, extent of tongue resection, and degree of volume restoration are strongly associated with swallowing and speech outcomes after glossectomy.

Most Patients With Uncertain Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Still Harbor Residual Disease
General Surgeryactive surveillanceEsophagectomy

Most Patients With Uncertain Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Still Harbor Residual Disease

By MedXY|May 26, 2026

In the SANO cohort, 85% of patients with uncertain post-chemoradiotherapy response had residual tumor at esophagectomy, supporting surgery for most, while highlighting a notable complete response subgroup among squamous cell carcinoma with

Molecular and Spatial Differences in the Tumor Microenvironment of High-Grade Serous Ovarian Cancer With Short vs Long-Term Survival
newsfibroblastshigh-grade serous ovarian cancer

Molecular and Spatial Differences in the Tumor Microenvironment of High-Grade Serous Ovarian Cancer With Short vs Long-Term Survival

By MedXY|May 26, 2026

This study found that advanced high-grade serous ovarian cancers from short-term survivors had more fibroblasts and stromal invasion signals, while tumors from long-term survivors showed stronger immune pathways, suggesting the tumor microe

PTEN Loss Drives MHC-I Evasion and Checkpoint Resistance in Microsatellite Stable Colorectal Cancer via NRF2-Dependent Autophagy
GastroenterologyMHC-Imicrosatellite stable colorectal cancer

PTEN Loss Drives MHC-I Evasion and Checkpoint Resistance in Microsatellite Stable Colorectal Cancer via NRF2-Dependent Autophagy

By MedXY|May 26, 2026

A Gut study links PTEN deficiency in MSS colorectal cancer to NRF2-driven autophagic loss of MHC-I, impaired CD8+ T-cell surveillance, and resistance to anti-PD-1 therapy, while identifying NRF2 inhibition as a potential sensitizing strateg

Intraperitoneal and Intravenous Paclitaxel Plus S-1 Improves Survival in Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial
GastroenterologyGastric Cancerintraperitoneal chemotherapy

Intraperitoneal and Intravenous Paclitaxel Plus S-1 Improves Survival in Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial

By MedXY|May 25, 2026

A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.

Prev
14 / 25
1…1213141516…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles